CalciMedica reported a FY 2025 net loss of USD 29.6 million and a loss per share of USD 1.97. R&D expenses were USD 15.2 million and G&A expenses were USD 7.9 million. Cash, cash equivalents and short-term investments totaled USD 13.0 million at December 31, 2025, which CalciMedica said is expected to fund its current operating plan into Q4 2026. On the pipeline, CalciMedica said internal and external reviews of unblinded Phase 2 KOURAGE data in acute kidney injury with acute hypoxemic respiratory failure found no evidence of drug-related toxicity with Auxora, after the trial was discontinued in January 2026 following an IDMC recommendation tied to a mortality imbalance. The company plans to discuss the KOURAGE data and potential future AKI development with the FDA in Q2 2026. In acute pancreatitis, CalciMedica said it expects to finalize the design of its pivotal Auxora program in H1 2026 following FDA engagement, and highlighted publication of Phase 2b CARPO results in eClinicalMedicine. The company also cited a JCI Insight publication supporting preclinical data for CM5480 in pulmonary arterial hypertension, with an IND submission anticipated in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603030700PR_NEWS_USPR_____LA99401) on March 03, 2026, and is solely responsible for the information contained therein.
Comments